Moreover, the downregulation of SRSF3 by antisense oligonucleotides (ASO) was shown to sensitize oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment [60]. This evidence concerns the gene SRSF3 and oral cavity squamous cell carcinoma.